Mumbai, Jan 31 (SocialNews.XYZ) Sun Pharmaceutical Industries Ltd on Wednesday reported a 16.52 per cent rise in net profit at Rs 2,523.75 crore for the October-December quarter of the current financial year on the back of strong sales in the domestic and US markets.
The company had reported a net profit of Rs 2,166.01 crore in the same period of the previous fiscal.
The pharma major’s board has declared an interim dividend of Rs 8.50 per share for 2023-24, up from Rs 7.50 per share interim dividend for the previous year.
The company’s revenue from operations rose 10 per cent to Rs 12,381 crore in the December quarter.
Sun Pharmaceuticals Managing Director Dilip Shanghvi said, "We are pleased by our continued broad-based growth, including in global specialty. We are keenly looking forward to EMA filing of Nidlegy in the coming months. Once approved, Nidlegy will significantly expand our onco-derm franchise in Europe."
The company’s share price shot up 4.88 per cent after the results to cross a one-year high at Rs 1,438.50.
Source: IANS
Gopi Adusumilli is a Programmer. He is the editor of SocialNews.XYZ and President of AGK Fire Inc.
He enjoys designing websites, developing mobile applications and publishing news articles on current events from various authenticated news sources.
When it comes to writing he likes to write about current world politics and Indian Movies. His future plans include developing SocialNews.XYZ into a News website that has no bias or judgment towards any.
He can be reached at gopi@socialnews.xyz
This website uses cookies.
